CryoCath Appoints Vice President, Europe
    Toronto Stock Exchange Symbol: CYT

    MONTREAL, July 2 /CNW/ - CryoCath Technologies Inc. (TSX: CYT), the
global leader in cryotherapy products to treat cardiac arrhythmias, today
announced the appointment of Frank Vandeputte as Vice President, Europe. Based
in CryoCath's new European headquarters in Leiden, The Netherlands,
Mr. Vandeputte will be responsible for leading the European business
operation. This includes the development and implementation of strategic and
operational business plans, with the objective of driving ongoing rapid sales
growth of the Company's innovative products in the European market.
    Mr. Vandeputte joins CryoCath with more than 20 years of experience in
the medical device industry. Most recently, he served as Area Vice President
Benelux and Nordic for the Sorin Group, based in Brussels. Prior to that he
was Vice President International Marketing with the Sorin Group. Prior to
Sorin, he held senior management positions with leading medical device
companies, including Baxter International Inc, Becton Dickinson and Guidant
Corporation. With Guidant, he has been providing leadership to their European
Cardiac Resynchronisation Therapy, Endovascular and Cardiac Surgery business,
and served as Country Manager for Germany as well.
    "With his proven leadership and medical device industry successes, Frank
will be an asset to our European commercial operations. He, and his successful
European leadership team, will spearhead the ongoing rapid growth of Arctic
Front in Europe," said Jan Keltjens, CryoCath President and CEO.
"Additionally, we have now opened our European headquarters in Leiden, the
Netherlands. This will allow us to better serve the needs of our expanding
customer base in Europe. By establishing a strong European presence and
enhancing our management team, we are continuing to execute on our strategy of
becoming a leader in atrial fibrillation therapy."

    About CryoCath
    CryoCath - - is a medical technology company that leads
the world in cryotherapy products to treat cardiac arrhythmias. With a
priority focus on providing physicians with a complete solution of catheter
products to treat cardiac arrhythmias, CryoCath has multiple products approved
in the U.S., across Europe and several ROW countries. The Company is
developing additional products to expand its pipeline of products to treat
cardiac arrhythmias.

    This press release includes "forward looking statements" that are subject
to risks and uncertainties, including with respect to the timing of regulatory
trials and their outcome. For information identifying legislative or
regulatory, economic, currency, technological, competitive and other important
factors that could cause actual results to differ materially from those
anticipated in the forward looking statements, see CryoCath's annual report
available at under the heading Risks and Uncertainties in the
Management's Discussion and Analysis section.

    %SEDAR: 00015053EF

For further information:

For further information: visit our website at, or
contact: Michael Moore, Investor Relations, Phone: (416) 815-0700 ext. 241,
Fax: (416) 815-0080, E-mail:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890